NASD · Healthcare · Biotechnology · USA
Revolution Medicines Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company uses its proprietary tri-complex technology platform to create small molecules designed for unconventional binding sites on RAS variants. Its pipeline comprises RAS inhibitors intended as monotherapy or combination treatments for pancreatic cancer, non-small cell lung cancer, and colorectal cancer.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Revolution Medicines Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on RVMD yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.